Anima attracts Takeda in potential multibillion-dollar deal

Tuesday, 23 March 2021, 19:22:00
Small-molecule mRNA translation expert Anima Biotech Inc. has landed a significant new preclinical research deal with Takeda Pharmaceutical Co. Ltd., covering as many as six programs for genetically defined neurological diseases. The deal starts with $120 million in up-front and preclinical research milestone payments for Anima, but altogether the two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts for the company, providing substantial support for its internal pipeline, Anima co-founder and CEO Yochi Slonim told BioWorld .
— BioWorld

MENA Biologics & Biosimilars Market Major Players Analysis Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited

Thursday, 18 March 2021, 13:41:57
MENA Biologics & Biosimilars Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
— OpenPR

Japan’s Takeda, Germany’s IDT Biologika to make Johnson & Johnson's single-dose Covid-19 vaccine

Monday, 15 March 2021, 19:19:40
BENGALURU/BERLIN: Japan's Takeda Pharmaceutical Co Ltd said on Monday it has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's single-dose Covid-19 vaccine. J&J's vaccine, authorized in the United States on Feb 27, is the first single-dose coronavirus vaccine alongside two-shot vaccines from Pfizer/BioNTech and Moderna Inc. The latest move will help ease some concerns in Europe about J&J's ability to meet production goals. The drugmaker has been working to expand the manufacturing capacity for its vaccine and previously tapped contract manufacturers such as Catalent and Emergent to scale up production and meet global supply goals. Merck & Co and France's Sanofi agreed to help make J&J's vaccine earlier this year. A European Union official told Reuters earlier this month J&J had flagged possible supply issues that may affect its plans to deliver 55 million vaccine doses to the bloc in the second quarter of the year. Under the contract, the capacity at IDT's Dessau site, previously reserved to make Takeda's dengue vaccine candidate, will be used to make J&J's Covid-19 vaccine for worldwide distribution.
— The Sun Daily

UPDATE 2-Takeda, IDT to make J&J's COVID-19 vaccine

Monday, 15 March 2021, 12:51:31
Japan's Takeda Pharmaceutical Co Ltd said on Monday it has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's single-dose COVID-19 vaccine.
— Reuters

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

Monday, 15 March 2021, 12:30:00
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be
— Business Wire